As per the companies recent presentation, there are many potential catalysts moving forward. Especially the last item.
Announcement of the appointment of Nigel Lange – Now• Humanitarian Device Exemption (HDE) filing with FDA for Bile Duct Cancer – Q2 2020 • Regulatory clearance in Hong Kong – anticipated 2H20• Regulatory clearance in Singapore – anticipated 2H20 • Additional long term survival data announced – 2H20• Expected first sale / procedure in UK – 2H20 • Expected first sale / procedure in EU – 2H20 • Regulatory clearance in US for Bile Duct Cancer – anticipated Q4 2020 • Regulatory clearance in Australia – anticipated 2021 • Expected first sale / procedure in US for Bile Duct Cancer – anticipated 2021Other announcements • Ongoing quarterlies announcing number of new hospital centre sign ups • Potential for partnering announcements for Pancreatic in China, Japan and other market
OSL Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)